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Exome Sequencing Identifies a REEP1 Mutation
Involved in Distal Hereditary Motor Neuropathy Type V
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The distal hereditary motor neuropathies (dHMNs) are a heterogeneous group of neurodegenerative disorders affecting the lower moto-
neuron. In a family with both autosomal-dominant dHMN and dHMN type V (dHMN/dHMN-V) present in three generations, we
excluded mutations in all genes known to be associated with a dHMN phenotype through Sanger sequencing and defined three poten-
tial loci through linkage analysis. Whole-exome sequencing of two affected individuals revealed a single candidate variant within the
linking regions, i.e., a splice-site alteration in REEP1 (c.304-2A>G). A minigene assay confirmed complete loss of splice-acceptor func-
tionality and skipping of the in-frame exon 5. The resulting mRNA is predicted to be expressed at normal levels and to encode an inter-
nally shortened protein (p.102_139del). Loss-of-function REEP1 mutations have previously been identified in dominant hereditary
spastic paraplegia (HSP), a disease associated with upper-motoneuron pathology. Consistent with our clinical-genetic data, we show
that REEP1 is strongly expressed in the lowermotoneurons as well. Upon exogeneous overexpression in cell lines we observe a subcellular
localization defect for p.102_139del that differs from that observed for the knownHSP-associatedmissensemutation c.59C>A (p.Ala20-
Glu).Moreover, we show that p.102_139del, but not p.Ala20Glu, recruits atlastin-1, i.e., one of the REEP1 binding partners, to the altered
sites of localization. These data corroborate the loss-of-function nature of REEP1mutations in HSP and suggest that a different mecha-
nism applies in REEP1-associated dHMN.The distal hereditary motor neuropathies (dHMNs), also
known as distal spinal muscular atrophies or spinal Char-
cot-Marie-Tooth (spinal CMT) diseases, are a group of clini-
cally and genetically heterogeneous disorders characterized
mainly by slowly progressive distal-limb-muscle weakness
and wasting, i.e., a lower-motoneuron phenotype. Minor
sensory disturbances or pyramidal signs may also be
present. The dHMNs have been subdivided into several
categories on the basis of phenotype and inheritance.1
There has been considerable recent progress on the genetic
side; 11 genes have been identified to date. Still, for a large
fraction of individuals affected with dHMN, a mutation
in an as-yet-unidentified gene has to be assumed.2 dHMN
typeV (dHMN-V [MIM600794]) is an autosomal-dominant
form in which muscle weakness and wasting are predomi-
nantly confined to the hands and often exclusively involve
thenar and/or interosseus dorsalis I eminences. Mutations
in two genes have been described so far. Missense muta-
tions in GARS (MIM 600287) were found in classical
dHMN and dHMN-V but also in the clinically overlapping
CMT2D syndrome (MIM 601472).3 In BSCL2 (MIM
606158), two missense mutations (c.263A>G [p.Asn88Ser]
and c.269C>T [p.Ser90Leu]) affecting glycosylation were
identified.4 They are both associated with a broad, often
intrafamilial spectrum of phenotypes, which includes clas-
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The Amplegia.5,6 Our recent finding that GARS and BSCL2
explain < 20% of cases suggests further genetic heteroge-
neity for dHMN-V also.7
The initial aim of the present study was to elucidate the
genetic defect in an Austrian family with classical dHMN/
dHMN-V, inherited in an autosomal-dominant fashion.
After informed consent and approval of the study were
obtained from the local ethical committee, nine members
(four affected individuals, three at-risk individuals, and
two spouses) were enrolled in the study (for pedigree see
Figure 1A). Within the first or second decade, all affected
individuals had presented with symptoms suggestive of
a predominant peripheral motor neuropathy that started
in the hands of two individuals and was exclusively
confined to the thenar and dorsalis interosseus I muscles
(Figure 1B). Family members II-1, III-5 and IV-5 showed
lower-limb involvement (Figures 1C and 1D) and walked
with a mild steppage gait. None of the affected individuals
showed elevated muscle tone or a spastic gait. Affected
individuals were diagnosed as either dHMN-V (II-1, III-3,
and III-5) or dHMN (IV-5) on the basis of clinical and
electrophysiological findings. Detailed clinical and electro-
physiological data are provided in Tables S1 and S2, respec-
tively, available online.
All dominant genes known to be mutated in dHMN
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Figure 1. Pedigree Structure, Clinical Images, REEP1 Sanger
Sequencing, and Minigene Assay
(A) Partial pedigree. Gender information was removed to preserve
anonymity. White and black symbols indicate unaffected and
affected individuals, respectively. Asterisks mark family members
whose DNA was available and was applied in linkage analysis.
Indicated below the identifiers are the results of REEP1 Sanger
sequencing (WT: wild-type allele, mut: mutant allele). The arrow
denotes the index case.
(B) Wasting of the thenar (B1) and interosseus dorsalis I (B2)
muscles in individual III-3.
(C) Distal-lower-limb atrophy in individual IV-5.
(D) Pes cavus foot deformity in individual III-5.
(E) Exemplary results of Sanger sequencing of REEP1 exon 5. The
stippled line indicates the intron/exon boundary. The arrowmarks
nucleotide c.304-2 (NM_022912).
(F) Minigene assay. RT-PCR onHeLa cells transfected with the indi-
cated constructs shows that mutation c.304-2A>G results in skip-
ping of REEP1 exon 5.
140 The American Journal of Human Genetics 91, 139–145, July 13, 2608014], SETX [MIM 608465], DCTN1 [MIM 601143], and
VAPB [MIM 605704]) were excluded previously through
the use of Sanger sequencing in the index proband III-5.8
We therefore performed multipoint linkage analysis by
applying Affymetrix GeneChip Human Mapping 10K
arrays (Affymetrix, Santa Clara, CA, USA) to the DNA of
all nine family members available. This revealed three
genomic intervals for which the affected individuals,
but not the unaffected individuals, share a common
haplotype. The corresponding LOD scores of 1.51 repre-
sented the maximum score, given the family structure
(Figure S1). The three regions reside in chromosomes 2p,
4q, and 8q. They do not contain any of the known genes
mutated in dHMN (see Table S3 for numbers of genes con-
tained in each region).2 As these findings argued strongly
for a mutation in a hitherto unknown gene for dHMN,
we turned to whole-exome sequencing. We selected indi-
viduals II-1 and IV-5 (grandparent and grandchild) in order
to minimize the expected number of shared variants.
Sequencing was performed on a Genome Analyzer HiSeq
2000 system (Illumina, San Diego, CA, USA) after in-
solution enrichment of exonic and adjacent intronic
sequences (SureSelect Human All Exon 50Mb kit, Agilent,
Santa Clara, CA, USA) and indexing of samples for
multiplex sequencing (Multiplexing Sample Preparation
Oligonucleotide Kit, Illumina). We performed 100 bp
paired-end runs, yielding 8.4 and 8.7 Gb of sequence for
individuals II-1 and IV-5, respectively. The average read
depths were 106 and 111, respectively, with 89% of the tar-
geted regions covered at least 20-fold. Read alignment was
performed with Burrows-Wheeler Aligner (version 0.5.8)
with application to the human genome assembly hg19.
Single-nucleotide variants and small insertions and
deletions were called with SAMtools (version 0.1.7). We
filtered variants to exclude HapMap SNPs present in
dbSNP132 that had an average heterozygosity greater
than 0.02, as well as those present in more than two of
approximately 800 in-house exomes from individuals
with unrelated diseases. Variant annotation was performed
with custom scripts. Only rare variants present in
both individuals were considered further. This approach
left 97 shared candidate variants. However, considering
those variants that were neither presented as rare variants
in the HapMap SNP database nor present in our in-house
controls resulted in a reduction to 53 nonsynonymous
sequence variations. Two of these mapped to a region of
linkage as defined above, but one of them (rs141088571)
was updated in the dbSNP135 database. The second
variant at position g.86,479,195 on chromosome 2
localized to a highly conserved nucleotide in intron 4 of
REEP1 (MIM 609139) (Figure S2A) and altered one of the
two critical bases in the splice acceptor of exon 5 (c.304-
2A>G, NM_022912; Genome Reference Consortium
h37.p5). As expected, complete segregation was subse-
quently confirmed with Sanger sequencing (Figure 1E).
In silico splice algorithms predicted complete loss of
splice-acceptor function (Table S4), thereby suggesting012
skipping of exon 5 (r.304_417del). Unfortunately, we could
not test for an effect on splicing using proband-derived
material; consistent with previous reports,9,10 all our
attempts to amplify REEP1 cDNA from peripheral blood
failed (data not shown).We therefore employed aminigene
assay based on a strategy originally developed for exon
trapping.11 An ~800 bp fragment, consisting of REEP1
exon 5 and ~350 bp of the neighboring introns, was ampli-
fied from DNA of the index proband and cloned into the
multiple cloning site (MCS) of the pSPL3 vector (Invitro-
gen, now Life Technologies, Carlsbad, CA, USA). Clones
derived from the wild-type allele or from the mutant allele
were identified through sequencing. HeLa cells (105 cells in
3.5 cmwells) were transfected with 3 mg of vector. Transfec-
tions of empty pSPL3 and mock transfections served as
positive and negative controls, respectively. After 16 hr,
total RNA was prepared (RNeasy Mini Kit, QIAGEN,
Hilden, Germany) and reverse transcribed with the use of
random hexamers (RevertAID First Strand cDNA Synthesis
Kit, Fermentas, now Thermo Fisher Scientific, Waltham,
MA). PCR amplification with vector-specific primers re-
vealed no product from mock-transfected cells and a
153 bp product from cells transfected with empty vector.
Transfection of pSPL3 containing the wild-type genomic
fragment resulted in an enlarged product (size ¼ 267 bp),
consistent with the splicing-mediated inclusion of the
exon 5 sequence. With the mutant fragment, in contrast,
a product of this size was virtually absent (Figure 1F). The
minigene assay thus confirmed that c.304-2A>G results
in skipping of exon 5 due to abolition of splice-acceptor
function. Though this exon, together with the preceding
exon 4, is also missing in one of four Reference Sequence
entries for the gene, the existence of significant amounts
of a corresponding mRNA species is not supported by
the > 100 REEP1-derived expressed sequence tag (EST)
sequences currently available at the UCSC genome
browser. We therefore conclude that c.304-2A>G, by
removing exon 5 from the major isoform, results in an
aberrant internal shortening of the encoded 201-residue
protein (p.102_139del). This removal of a significant
portion of the primary structure (almost 20% of the
proteins’ residues) that is highly conserved in evolution
(Figure S2B), together with perfect segregation and the
lack of any other candidate variant, strongly suggested
that REEP1 c.304-2A>G was the mutation underlying
dHMN in the family studied. Moreover, the variant was
neither found in > 10,000 publicly available control chro-
mosomes (~4,000 exomes in the National Heart, Lung, and
Blood Institute [NHLBI] Exome Variant Server; 1,094
genomes in the 1000 Genomes database) nor in our
previous analysis of the gene in 366 control individ-
uals,10 in our 800 in-house exomes, or in 88 specifically
screened local control individuals (data not shown).
Although we cannot definitively exclude the presence of
a copy-number aberration or of a deep intronic mutation
in the linking regions, it appears highly likely that REEP1
can be mutated in individuals with dominant dHMN.The AmHeterozygous REEP1 mutations have previously been
shown to underlie SPG31 (MIM 610250), a relatively
frequent, autosomal-dominant form of hereditary spastic
paraplegia (HSP).9 In the HSPs, degeneration of the upper
motoneuron leads to a progressively spastic gait.12 The
vast majority of individuals suffering from SPG31 show
clinically pure HSP; i.e., pyramidal signs predominate,
and there is no evidence for lower-motoneuron involve-
ment. Consistent with these clinical and genetic observa-
tions, endogenous REEP1 has been detected in the
brain13 and in cultured cortical neurons.14 Our initially
surprising finding that a REEP1 mutation underlies
a lower-motoneuron phenotype prompted us to address
the expression of the gene in the spinal cord. The exon
2–6 cDNA sequence of murine Reep1 was amplified
from whole-embryo cDNA and cloned into pCRII-TOPO
(Invitrogen). Following linearization by appropriate
restriction digests, sense and antisense riboprobes were
transcribed by T7 and SP6 RNA polymerases, respectively
(New England Biolabs, Ipswich, MA). Riboprobes were
labeled with digoxigenin (DIG RNA Labeling Kit, Roche
Diagnostics, Mannheim, Germany) according to the
manufacturer’s instructions. Spinal cord was obtained
from 4-month-old, fresh-frozen C57BL/6 mice, and series
of frontal 20 mm cryotome sections were thawed onto glass
slides (SuperFrost Plus, Menzel, Braunschweig, Germany).
Representative slides from the cervical, thoracal, and
lumbar regions were hybridized with the labeled ribo-
probes as described previously.15 For neuroanatomical
orientation, adjacent sections were stained with thio-
nine.16 This staining, by highlighting all neuronal peri-
karya, revealed the typical butterfly shape of the gray
matter (Figure 2, left panel). No signal was obtained
upon hybridization of the Reep1 sense probe (not shown),
whereas the signal from the antisense probe specifically
labeled neurons with large somata in the ventral horns.
This pattern, which was observed at all rostrocaudal levels
analyzed (Figure 2, right panel), indicates predominant
expression of Reep1 in the spinal cord motoneurons and,
therefore, is consistent with a causative association of the
REEP1 alteration with the lower-motoneuron phenotype
in our family.
A total of 40 HSP-associated REEP1mutations have been
reported thus far.9,10,17–22 As most of these are truncating
(i.e., create a preterminal stop codon), nonsense-mediated
decay (NMD) of the mutant mRNA is likely.23 Conse-
quently, HSP-associated REEP1 mutations have been
proposed to act by a (haplo)insufficiency loss-of-function
mechanism.10 The c.304-2A>G mutation identified in
the present study, in a family with dHMN rather than
HSP, is predicted to result in an mRNA that lacks exon 5
(r.304_417del). Interestingly, this is the only exon of
REEP1 whose absence does not result in a frameshift and,
thus, would not trigger NMD of the mRNA. Instead,
mRNA from the mutant allele should be present at normal
levels and result in translation of a normal amount of
mutant protein (p.102_139del). We therefore decided toerican Journal of Human Genetics 91, 139–145, July 13, 2012 141
Figure 2. Expression of Reep1 in the Spinal Cord at Different
Rostrocaudal Levels
Alternating spinal cord sections (10 mm) from 4-month-old adult
mice were stained with thionine or hybridized with a Reep1-
specific RNA probe. Thionine labels all neuronal cell bodies,
thereby defining the gray matter, whereas the signal from Reep1
in situ hybridization is restricted to large somata in the ventral
horns.investigate the consequences of removing residues 102-
139 from the protein. The coding sequence of human
REEP1, with inclusion of the stop codon, was amplified
from brain-derived cDNA (Human Multiple Tissue cDNA
Panel I, Clontech, Palo Alto, CA, USA) and cloned into
the MCS of pCS2þ; thus, expression was enabled under
the cytomegalovirus promotor of an mRNA coding for the
untagged protein. Mutation c.304_417del was introduced
through the application of centrally overlapping, semi-
nested PCRs. Using a similar strategy, we also created
c.59C>A, i.e., a recurrent HSP-associated alteration,9,10
which, due to its representation of a missense change
(p.Ala20Glu), is also predicted to not trigger NMD. The
identity of all three constructs was verified through
sequencing. After seeding of HeLa cells into 8-well
chamber slides (Lab-Tek, Thermo Fisher Scientific) and
growth for 16 hr, constructs were transfected with lipofect-
amine (Invitrogen) and cells were grown for another 20 hr
to allow for expression of the vector-derived mRNAs and
translation of the corresponding proteins. Cells were
then fixed in 4% paraformaldehyde, permeabilized in
0.1% Triton X-100/PBS for 15 min, and incubated in
blocking buffer containing goat serum for 30 min. Overex-
pressed REEP1 was detected with the use of a rabbit poly-
clonal antibody (SAB2101976, Sigma-Aldrich, St. Louis)
and visualized with the use of appropriately labeled
secondary antibodies. After counterstaining of the cell
nuclei with the use of DAPI, chambers were removed and
slides were mounted in ProLong antifade reagent (Invitro-
gen). Images were obtained via confocal laser-scanning
microscopy (LSM510 Meta, Zeiss, Oberkochen, Germany).
Wild-type REEP1 localized to a cytoplasmic network142 The American Journal of Human Genetics 91, 139–145, July 13, 2(Figure 3A, upper panel). Similar to findings on COS7 cells
in a previous report,14 co-overexpression with green fluo-
rescent protein (GFP)-tagged Sec61b revealed a high degree
of overlap (Figure S3), thereby confirming a targeting to
the tubular portion of the peripheral endoplasmic retic-
ulum (ER).14 The p.Ala20Glu construct showed a severely
altered localization. Whereas a reticular pattern was never
observed, numerous punctate structures, some of which
had a hollow, doughnut-like appearance, were present
throughout the cytoplasm (Figure 3A, middle panel). The
apparent failure of p.Ala20Glu to localize to the ER is
consistent with the proposed involvement of the hydro-
phobic N terminus in subcellular targeting.10,14 It also
corroborates the haploinsufficiency mechanism generally
considered to give rise to HSP-causing REEP1 muta-
tions:10 unavailability of the protein at the site of physio-
logical function would effectively resemble an absence of
the protein. Interestingly, REEP1 p.102_139del showed
a completely different (mis)localization. Similar to the
wild-type, some of the signal labeled a reticular network
that colocalized with GFP-tagged Sec61b (Figure S3). In
addition, however, we observed 5–20 irregularly shaped
compact structures per cell, which were confined to the
cytoplasm. They were of varying size, with the largest
ones measuring several mm and occupying perinuclear
positions (Figure 3A, lower panel). Taken together, these
observations represented an initial hint that the pathome-
chanism that applies to p.102_139del and leads to dHMN
may be fundamentally different from the mechanism rele-
vant for HSP-associated REEP1 mutations.
Recent in vitro studies have provided some ideas
regarding the probable cellular roles of the family of
REEP proteins. REEP5, also known as DP1, has been shown
to act in concert with the reticulons in generation and/or
stabilization of membrane curvature in the tubular ER.24
Such ‘‘shaping’’ activity depends on the presence of
a central, unusually long hydrophobic domain,25 which
is found in all REEPs and, thereby, defines the protein
family.14 In REEP1, it occupies residues 37 to 76 and, there-
fore, remains unaffected by both the p.Ala20Glu missense
change and the p.102_139 deletion. As it also represents an
intramembrane site of interaction with numerous other
ER-resident proteins,14,25,26 we hypothesized that REEP1
mislocalization may have an influence on the localization
of its binding partners. We chose human atlastin-1, a well-
characterized REEP1 interactor,14 and cloned it behind
a DsRed tag (pDsRed-C1, Clontech). Overexpression in
HeLa cells revealed the reticular pattern (Figure 3B), which
has been reported previously and was shown to represent
tubular ER.27 Upon co-overexpression of atlastin-1 with
wild-type REEP1, a wide range of localization patterns
was observed for both proteins. In a fraction of cells,
targeting of REEP1 was virtually unaltered whereas some
atlastin-1 was redistributed to small punctuate structures
in the cell’s periphery (Figure 3C, upper panel). This
pattern resembled the one previously observed in COS7
cells.14 In other cells, there were many more (up to several012
Figure 3. Subcellular Distribution of Overexpressed REEP1 and
Atlastin-1
HeLa cells were transfected with the indicated constructs.
Untagged REEP1 was detected by immunofluorescence, atlastin-1
by fluorescence of the DsRed tag. Nuclei were stained with DAPI.
The scale bar represents 20 mm.
The Amhundred) punctuate structures, and these also represented
a major site of REEP1 localization (Figure 3C, lower panel).
Co-overexpression of atlastin-1 with REEP1 p.Ala20Glu, in
contrast, did not have any effect on atlastin-1 distribution.
Moreover, there was hardly any overlap with the structures
labeled by REEP1 p.Ala20Glu (Figure 3D, upper panel).
Finally, atlastin-1 and REEP1 p.102_139del completely
colocalized upon co-overexpression. Notably, this in-
cluded a recruitment of atlastin-1 to the 5–20 large perinu-
clear ‘‘clumps’’ characteristic of REEP1 p.102_139del
(Figure 3D, lower panel; compare Figure 3A, lower panel).
Our coexpression data, therefore, strongly argue for the
association of an interaction-mediated, possibly toxic
gain-of-function effect with p.102_139del (with atlastin-1
not necessarily representing the pathologically relevant
interactor), but not with p.Ala20Glu. We suggest that, in
general, heterozygous loss-of-function mutations in REEP1
entail upper-motoneuron pathology, whereas mutations
possibly gaining a toxic function lead to a lower-moto-
neuron phenotype. The mechanistic basis of this differ-
ence remains enigmatic. Its elucidation, however, can be
expected to significantly enhance our understanding of
the diverse group of motor neuron diseases.
Our REEP1 mutation associated with classical dHMN
differs from the HSP-associated alterations in that it (1)
leaves the N-terminal half intact, (2) removes exon 5 resi-
dues, and (3) is unlikely to trigger NMD. Only a small frac-
tion of changes in REEP1 are expected to have similar
consequences (other alterations which affect the exon 5
splice acceptor, genomic deletions of exon 5, and small
in-frame deletions in exon 5). REEP1-associated dHMN
may therefore be a rare condition. Consistent with this
notion, our screening of a well-characterized cohort of
nine additional dHMN-V index cases, for whom GARS
and BSCL2 had already been excluded,7 failed to identify
a second family. One may, however, imagine that certain(A) Subcellular targeting of wild-type REEP1 is differentially altered
by the indicated pathogenic mutations. Wild-type REEP1 localizes
to a cytoplasmic network representing ER14 (upper panel, see also
Figure S3A). REEP1 p.Ala20Glu is exclusively found in numerous
small, sometimes hollow structures (middle panel). REEP1
p.102_139del, in addition to being found in the ER network (see
also Figure S3B), accumulates in 5–20 compact structures, the
largest of which occupy a perinuclear position (lower panel).
(B) Atlastin-1, in single transfections, is targeted to a highly
branched ER network.27
(C) Cotransfections of wild-type REEP1 and atlastin-1 result in
a spectrum of distribution patterns. Shown are two extremes,
i.e., a cell in which REEP1 distribution appears unaltered whereas
some atlastin-1 is redistributed to small peripheral spots (upper
panel) and a cell in which atlastin-1 and much of REEP1 coaccu-
mulate in cytoplasmic punctate structures, which are evenly
distributed throughout the cytoplasm (lower panel).
(D) Mutation p.102_139del, but not p.Ala20Glu, impacts on the
subcellular distribution of atlastin-1. Whereas cotransfection of
REEP1 p.Ala20Glu leaves the atlastin-1 pattern unaltered (upper
panel), REEP1 p.102_139del recruits atlastin-1 to the large perinu-
clear structures also observed in single transfections of this mutant
protein (lower panel, compare lower panel in A).
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mutations confer both a loss- and a gain-of-function effect.
Pertinent alterations would be predicted to (1) leave the
N-terminal half intact, (2) remove or alter exon 5 residues,
and (3) partially trigger NMD and partially escape it. A total
of five such mutations have been described (nomenclature
refers to NM_022912): c.320T>C (p.Leu107Pro and defec-
tive splicing predicted),18 c.337C>T (p.Arg113X),19 c.340_
347del (p.Ser114fsX70),18 c.345C>A (p.Tyr115X),18 and
c.366G>T (p.Gly122GlyfsX46).22 In the one case
analyzed, presence of at least some of the mutant mRNA
was shown.22 Clinical details are available for this
(c.366G>T) and for one of the other mutations
(c.337C>T).19 Strikingly, in both cases, the diagnosis was
complicated HSP, based on clear signs of an additional
motor neuropathy and the wasting of the small hand
muscles in one affected individual.19,22 It thus appears
that the combination of too little REEP1 in general and
the presence of possibly toxic gain-of-function REEP1
can result in a mixed HSP-dHMN phenotype.
Our identification of REEP1 to represent a gene mutated
in classical dHMN considerably broadens the phenotypic
spectrum associated with REEP1 mutations. This signifi-
cant qualitative extension resembles the case of ATL1
(MIM 606439), mutations of which are classically associ-
ated with HSP (SPG3A [MIM 182600]) and have recently
been found by us to be associated with hereditary sensory
neuropathy (HSN1D [MIM 613708]) as well.28 The REEP1
clinical spectrum now strongly matches that of BSCL2
missense mutations p.Asn88Ser and p.Ser90Leu.4 Both
protein products are also tightly associated with ER-related
functions.14,29 Given the two BSCL2 mutations found all
along the phenotypic spectrum5 versus a clear genotype-
phenotype correlation for REEP1 (in the present study),
the mechanisms underlying differential damage of lower
and upper motoneurons appear to differ. From the clinical
genetic perspective, however, our findings indicate that
both BSCL2 and REEP1 should be considered for a spectrum
of disorders ranging all the way from HSP to dHMN.
More generally, they strengthen the recent notion that
similar molecular themes may underlie clinically differing
axonopathies.30Supplemental Data
Supplemental Data include three figures and four tables and can
be found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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